Shun-Ichiro Ota
Research Subjects
Shun-Ichiro Ota has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Ayako Takaki
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka City, Japan
2 shared publications- Hiroaki Niiro
Department of Medical Education, Graduate School of Medical Sciences, Kyushu University , Fukuoka
2 shared publications - Hirofumi Tsuzuki
Universal Cells, Inc., Seattle, Washington
2 shared publications - Hiroshi Tsukamoto
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
2 shared publications - Kohta Miyawaki
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
2 shared publications - Koichi Akashi
Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan
2 shared publications
Latest Publications
- 22 July 2019
- Published by Wiley in Cancer Reports
- Vol. 2 (5) , e1200
Clostridium difficile infection in fever patients with gynecological malignancies
Background: Although Clostridium difficile infection (CDI) often results in severe manifestations due to toxin‐producing clostridium, the correlation between CDI and having a fever in gynecological malignancies is not completely understood.Aims: The incidence, and clinical features, and clinical management of CDI in patients with gynecological malignancies who have fevers were investigated, and the clinical managements of this complication are discussed.Methods and results: We retrospectively reviewed 485 patients newly diagnosed with invasive gynecological cancers who underwent anticancer treatment between July 2012 and December 2016. The diagnosis of CDI was performed using enzyme immunoassays for C difficile glutamate dehydrogenase and toxin A/B enzyme immunoassay. The cumulative risk of CDI was 9.5% (six of 63) in overall fever patients and 6.3% (six of 95) in patients with fever episodes. Two CDI patients (33.3%) did not show diarrheal symptoms, with the fever of unknown origin criteria prompting their CDI testing and diagnosis. CDI patients were treated using vancomycin or metronidazole without suffering from fatal clinical course. Overall, eight patients with gynecological malignancies were diagnosed with CDI, including two patients with fever lower than 38.5°C. The cumulative risk of CDI was 0.48% (eight of 1652) for all admitted patients and 1.6% (eight of 485) in those with gynecological malignancies. Of all the patients with confirmed CDI, only one had a history of administration of antibiotics prior to onset of CDI symptoms.Conclusion: CDI does not always present with typical manifestations in malignancy patients. Investigation of CDI, regardless of gastrointestinal symptoms or history of antibiotic use, is warranted in cases of fever of unknown origin in gynecological malignancy.
- 22 July 2019
- Published by Wiley in Cancer Reports
- Vol. 2 (5) , e1200
Clostridium difficile infection in fever patients with gynecological malignancies
Background: Although Clostridium difficile infection (CDI) often results in severe manifestations due to toxin‐producing clostridium, the correlation between CDI and having a fever in gynecological malignancies is not completely understood.Aims: The incidence, and clinical features, and clinical management of CDI in patients with gynecological malignancies who have fevers were investigated, and the clinical managements of this complication are discussed.Methods and results: We retrospectively reviewed 485 patients newly diagnosed with invasive gynecological cancers who underwent anticancer treatment between July 2012 and December 2016. The diagnosis of CDI was performed using enzyme immunoassays for C difficile glutamate dehydrogenase and toxin A/B enzyme immunoassay. The cumulative risk of CDI was 9.5% (six of 63) in overall fever patients and 6.3% (six of 95) in patients with fever episodes. Two CDI patients (33.3%) did not show diarrheal symptoms, with the fever of unknown origin criteria prompting their CDI testing and diagnosis. CDI patients were treated using vancomycin or metronidazole without suffering from fatal clinical course. Overall, eight patients with gynecological malignancies were diagnosed with CDI, including two patients with fever lower than 38.5°C. The cumulative risk of CDI was 0.48% (eight of 1652) for all admitted patients and 1.6% (eight of 485) in those with gynecological malignancies. Of all the patients with confirmed CDI, only one had a history of administration of antibiotics prior to onset of CDI symptoms.Conclusion: CDI does not always present with typical manifestations in malignancy patients. Investigation of CDI, regardless of gastrointestinal symptoms or history of antibiotic use, is warranted in cases of fever of unknown origin in gynecological malignancy.
- 1 February 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (2) , AB166
Sophora Flavescens Suppresses Lung Eosinophilia By Inhibiting Both Eosinophil Hematopoiesis and Migration
- 1 February 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (2) , AB166
Sophora Flavescens Suppresses Lung Eosinophilia By Inhibiting Both Eosinophil Hematopoiesis and Migration
- Open Access
- 1 February 2015
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 135 (2) , AB161
IL-33 Induces Cytokine Production By Lineage-Committed Myeloid Progenitors and Positively Regulates Eosinophil Hematopoiesis in IL-5-Dependent Manner
- 1 February 2015
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 135 (2) , AB161
Open AccessIL-33 Induces Cytokine Production By Lineage-Committed Myeloid Progenitors and Positively Regulates Eosinophil Hematopoiesis in IL-5-Dependent Manner